original human tumor. 45 These BTSCs demonstrate immunoreactivity for CD133, a primitive progenitor cell marker, and appear to be the tumor-initiating cells not only in mouse xenografts but also potentially in spontaneous human GBM. Furthermore, when BTSCs were induced to differentiate in vitro, they retained the ability to form neurospheres when cultured in stem cell-supportive media, an ability that is unique to BTSCs. Thus, BTSCs appear to have the capacity to revert from a terminally differentiated state back to a more primitive state, a characteristic distinct from normal NSCs and consistent with cells found in other malignancies. 51 The ability of cells isolated from human tumors to self renew and contribute to various cell types in both in vitro and in vivo tumorigenesis models establishes a potential mechanism for the complex heterogeneity characteristic of GBM and highlights the need for therapeutic strategies targeting not only malignant, more differentiated GBM tumor cells, but also GBM stem cells that likely contribute to the inevitable recurrence of this disease. The potential phenotypic differences between GBM stem cells and normal NSCs may be subtle, and may in fact be undetectable by currently used clinical tests. Additionally, the source of BTSCs may not be the tumor itself. In at least one study in which a spontaneous mouse model of GBM was used, it was found that tumor-initiating cells might migrate from a separate location within the brain, only to repopulate an area with a favorable microenvironment for tumor growth. 53 Although the combination of invasiveness, the ability to become migratory, and complexity of cellular composition in human GBMs represents a formidable challenge for effective therapy, the identification of BTSCs provides a rational target for new therapies, because these cells appear to be the tumor-initiating component of GBM.
Complex Heterogeneity and Genetic Mutations
Numerous genetic mutations have been identified in GBM that have been postulated to contribute to gliomagenesis. Alterations in tumor suppressors are the genetic lesions most commonly found. Retinoblastoma protein, the RB-1 gene product, is present ubiquitously and at relatively constant levels throughout the body. 1 In its dephosphorylated state, this protein functions as a tumor suppressor by sequestering molecules that normally promote progression through the cell cycle. 1, 40 Cell proliferative signals, such as RTK activation through ligand binding, in turn promote phosphorylation of RB protein in the nucleus. The progressive state of phosphorylation causes RB to release bound transcription factors such as E2F proteins, allowing them to drive progression of a cell through the mitotic cell cycle. Thus, RB plays a key role in modulating cell division, largely based on its level of phosphorylation. The RB gene is commonly mutated or deleted in primary human GBM specimens, 17 thereby implicating RB-mediated cell cycle regulation in the progression of GBM.
Deletion or alteration of the p53 tumor suppressor is present in 25 to 30% of GBMs 29, 35, 48 and has also been extensively studied in these tumors. 22 The p53 gene is not commonly expressed at high levels in healthy tissues; its expression is induced by a variety of mechanisms usually implicated in the induction of DNA damage, like that caused by radiation exposure. 1, 22 When present in the cell, p53 promotes the transcription and translation of proteins that block progression through the cell cycle, allowing DNA damage to be repaired. 27 Loss of p53 allows cells with DNA damage to progress through the cell cycle unchecked, perpetuating or compounding the DNA damage. 1, 22, 46 Direct mutation, deletion, or loss of expression of p53 is commonly observed in GBMs, as in many other solid tumors. 22 Furthermore, changes in genes upstream of p53 in this pathway are also commonly found in tumors. Amplification or overexpression of MDM2 occurs in 10 to 15% of GBMs, resulting in a blunted or absent p53 response, and has in some studies been associated with poor prognosis in patients with GBM. 19, 38, 39, 41 The MDM2 binds to and sequesters p53, promoting its rapid degradation within the cell, thus preventing transcription of antiproliferative genes. 33 The MDM2 is in turn regulated by another gene product, human p14ARF (called ARF in this paper); ARF antagonizes MDM2, releasing p53 inhibition to induce cell cycle arrest. 37 Although ARF is located in the INK4A genomic locus and shares exons 2 and 3 with p16
INK4A
, it differs in structure and function due to a frameshift caused by splicing from an alternative exon 1. 24 This second gene encoded by the INK4A locus, p16
, also functions as a tumor suppressor, but with a different mechanism and specificity than ARF. The p16
INK4A locus indirectly regulates RB by blocking the action of cyclin-dependent kinases, preventing phosphorylation of RB, and maintaining RB-mediated inhibition of cell cycle progression. 22 Thus, each of the genes encoded by the INK4A locus regulate tumor suppressors, and loss of each has been shown to cause transformation of cells to a malignant phenotype. Therefore, both are considered tumor suppressors and have been implicated in gliomagenesis. Recent studies in mice indicate that ARF may play a more prominent role in gliomagenesis than p16, although there may be differences in the function of these proteins in mice compared with humans. 22, 24 Separate studies have demonstrated variability of gene expression in different sets of GBMs. 16, 28, 32 In particular, tumors expressing the EGFR, which is associated with a particularly poor prognosis, can clearly be identified by microarray expression analysis. 32 In other studies, investigators have been able to identify subtypes of GBM based on their molecular signature. 21, 28, 32, 34 Some of these researchers have further demonstrated that overexpression of specific genes correlates with a more favorable prognosis, although the mechanism by which they were overexpressed was not evaluated. In one study, expression analysis was correlated with copy number changes determined using comparative genomic hybridization, and global gene expression changes were observed in genes not associated with chromosomal regions implicated in gene amplification or deletion. 34 Specifically, copy number changes in genes located on chromosome 10 were associated with global gene expression changes. Interestingly, loss of heterozygosity at the chromosomal location 10q23 is a common feature in GBM.
Chromosomal deletions, mutations, and amplifications all play roles in the development of malignancies, including GBMs. Many GBMs may have common features attributable to these genetic changes. Nevertheless, the circuitous path each individual tumor has followed to reach malignant transformation is likely unique to that tumor and patient, and thus may require therapeutic strategies tailored specifically for each patient and GBM.
Aberrant Signal Transduction
In addition to loss of tumor suppressor function, gain of function changes also occur in GBMs and, as in other tumors, often affect signal transduction pathways (Fig. 1) . The EGFR is an RTK that is commonly overexpressed in GBMs, and this overexpression typically occurs as a result of gene amplification. 4, 14, 52 The EGFR-mediated signal transduction results in activation of a number of downstream pathways including PI3K-AKT and RAS-MAPK, inhibiting apoptosis and driving proliferation.
14 Alternatively, deletion within the EGFR coding sequence can result in the expression of a truncated, mutant EGFR protein that signals constitutively.
Other mutations common in GBM affect RTKs other than EGFR. Expression of PDGFR␤ as well as its ligand is frequently found in GBMs. 31 The PDGFR␤ activates RAS-MAPK and PI3K-AKT as well as JAK-STAT signaling, which is involved in cell survival, proliferation, and differentiation. 31 Specific dysregulation of RAS-MAPK caused by loss of the NF1 gene in neurofibromatosis Type 1 syndrome has been associated with an increased risk of malignant astrocytomas in affected individuals. 53 Therefore, the RAS-MAPK signaling cascade has been presumed to be important for gliomagenesis. Recent evidence indicates, however, that mutant EGFR and overexpressed wild-type EGFR signal preferentially down divergent pathways in GBM; down RAS-MAPK and PI3K-AKT pathways, respectively. 52 Inducible models of tumorigenesis in mice have yielded findings that particular tumors become dependent on specific mutations, and that repression of the initiating oncogenic stimulus can result in widespread apoptosis and tumor regression. 8, 10, 18, 30 Targeting of specific molecular defects on which tumor cells rely is the goal of many novel therapeutic strategies ( Table 1 ). Many of these strategies, however, depend on comprehensive mutation or expression analysis. Because RTKs and signaling pathways represent attractive targets for molecular therapeutics, distinguishing the nature of pathway activation in individual tumors will be important for the selection of the appropriate therapeutic modality. Again, the pathway to complete malignant transformation is likely unique in every patient and, although similar pathways are implicated in gliomagenesis by changes in various upstream signaling molecules, the overall mechanisms of pathway activation in
Neurosurg. Focus / Volume 19 / October, 2005
Emerging concepts in glioma biology: implications for treatment each tumor may play an important role in the ultimate malignant phenotype. Analysis of the pathways involved in individual tumors should therefore be performed to assist in the selection of therapies that address the unique biology of the specific tumor.
For instance, molecular inhibitors of MDM2 have been recently developed for clinical use. These compounds, called "nutlins," interfere with the interaction between MDM2 and p53, releasing p53 from negative regulation and allowing transcription of cell cycle inhibitory molecules. 50 Because MDM2 is the second most commonly amplified gene in GBM, use of nutlins in this disease seems a rational therapeutic strategy. Nevertheless, this approach is likely to be most effective only in patients with MDM2 overexpression or low p14 ARF expression. Clinical trials using nutlins as a component of therapy should therefore be designed to include expression and mutation analysis of these two genes as a criterion for patient selection.
Expression Analysis for Rational and Patient-Tailored Therapy
An increasing body of evidence demonstrates the utility of expression profiling in stratification of patients with GBM in terms of tumor classification and survival. Unfortunately, a marker of survival in GBM is a relative term that belies the fact that less than 1% of patients survive more than 5 years. 25, 42 Although identification of markers relevant for patient stratification will undoubtedly contribute to improvements in treatment modality, it is important to expand these studies to include the identification of rational therapeutic targets, which seems a more compelling goal in evaluation of GBM at the transcriptional level.
In addition to intertumoral heterogeneity, studies evaluating differential gene expression within the same tumor have demonstrated intratumoral heterogeneity between core GBM tissue and invasive, proliferating peripheral tumor tissue. 16 Expression differences in one study correlated with differences in the intensity of contrast enhancement on magnetic resonance imaging. 15 This intratumoral heterogeneity again highlights the need for multifaceted modalities addressing all aspects of the biology of GBMs. These studies demonstrate the utility of expression profiling in the stratification of patients as well as the selection of targeted molecular and gene therapies used for successful treatment of this disease. The identification of BTSCs as candidates for the true tumor-initiating cells poses an interesting challenge for conducting routine, high-throughput gene expression analysis of GBMs to tailor therapy to rational targets. It is vital to kill the BTSCs as well as the more differentiated tumor cells to achieve the maximum antitumor effect. Accordingly, it may be critical to purify CD133-positive BTSCs for expression analysis to determine which class of drugs is most likely to kill these cells. In addition, expression analysis could be conducted in the CD133-negative tumor cells to identify a second drug tailored for their elimination.
CONCLUSIONS
In-depth expression analysis with respect to mutation status has not been performed with GBMs to the same extent as with other cancers. 2, 26, 49 With the development of molecular inhibitors targeting multiple pathways implicated in gliomagenesis, the combination of expression analysis and mutation status may be the next step in enabling the development of therapeutic modalities better tailored for individual disease characteristics. It is clear that the appropriate drugs for GBM will not be the same for all patients, and that choosing the best drug may require routine expression analysis. Therefore, expression analysis may be most useful as a standard clinical test performed before drug therapy commences to choose rationally patient-tailored drugs that target the appropriate molecular pathways. For instance, expression analysis could be conducted immediately after resection in multiple biopsy samples of core and invasive regions of the tumor, perhaps identified before resection on magnetic resonance imaging.
Implementing expression analysis as a standard clinical test, however, will require significant changes in the way clinicians approach GBM treatment, as well as the development of substantial infrastructure for rapid, high-throughput expression and mutation analysis of tumor tissue. The challenge of interpreting large data sets generated from routine, high-throughput array analysis from individual tumors will require an expansion of expertise from academic, researchoriented studies to wider clinical practice. Despite these obstacles, it is vital to take into account the genetic mutations present in the patient's individual tumor before the use of drugs that target molecular pathways can ever be expected to achieve maximal clinical efficacy. Furthermore, it is important to consider that GBMs are composed of a group of related but genetically distinct tumor cells, containing both BTSCs and differentiated tumor cells, and capitalize on this knowledge by using therapies that target all populations present in the tumor. 
